NHS Surgeon First in Europe to Implant TELA Bio’s OviTex LPR Reinforced Tissue Matrix
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) has announced the first use of its OviTex LPR Reinforced Tissue Matrix in Europe.
Read MoreHernias
TELA Bio Initiates BRAVO II Study of OviTex® for the Robotic Repair of Ventral Hernias
MALVERN, PA — TELA Bio, Inc. (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue …
Read More TELA Bio Announces 12-Month Analysis from BRAVO Study of OviTex
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue …
Read More
TELA Bio Appoints Renowned Surgeon as Vice President of Clinical Development
MALVERN, PA — TELA Bio, Inc. (Nasdaq: TELA), an innovative MedTech company focused on advancing the field of soft-tissue reconstruction, announced that it has welcomed Bruce Freedman, M.D., FACS as …
Read More TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair
MALVERN, PA — TELA Bio, Inc. announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.
Read More TELA Bio Announces Interim Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair
MALVERN, PA — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in …
Read More TELA Bio, Inc. Announces Poster Presentations at the 2020 Minimally Invasive Surgery Symposium (MISS)
MALVERN, PA — TELA Bio, Inc. (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet …
Read More